<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23677325</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-679X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical and vaccine immunology : CVI</Title><ISOAbbreviation>Clin Vaccine Immunol</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of antipolio antibodies among children &lt;15 years of age in border provinces in China.</ArticleTitle><Pagination><StartPage>1070</StartPage><EndPage>1075</EndPage><MedlinePgn>1070-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/CVI.00092-13</ELocationID><Abstract><AbstractText>Despite remarkable progression toward polio eradication worldwide, wild poliovirus (WPV) importation has been a great challenge for China, as it shares borders with countries where WPV is endemic. The objective of this study was to estimate poliovirus antibody seroprevalence among children &lt;15 years of age in 3 border provinces (Yunnan Province, Tibet Autonomous Region, and Xinjiang Uygur Autonomous Region) in China. A cross-sectional, hospital-based study was undertaken in 3 border provinces in 2010. Individuals &lt;15 years old who visited hospitals at the prefecture level or above to have their blood drawn for any reason were invited to participate in our study. Neutralizing antibody titers to polio serotypes 1 (P1), P2, and P3 were assayed according to the World Health Organization manual for the virological investigation of polio. Antibody titers of &#x2265;8 were considered positive. Among the 1,360 subjects enrolled, 1,220 (89.7%), 1,259 (92.6%), and 1,112 (81.8%) were seropositive to P1, P2, and P3, respectively, and 1,051 (77.3%) subjects were seropositive to all three serotypes. The highest seropositive rates were observed in Xinjiang Uygur Autonomous Region. By age, 3- to 5-year-old subjects had the highest rate of seropositivity, and seropositivity decreased significantly with increasing age. The risk of WPV importation will continue until WPV transmission has been interrupted worldwide. Consistent with the Global Polio Eradication Initiative's polio endgame strategy, China must maintain its polio-free status by ensuring adequate population immunity against polio. Because immunity wanes with increasing age, a booster dose with bivalent type 1 and 2 oral poliovirus vaccine could be considered for teenagers in China.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>HaiBo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Chinese Center for Disease Control and Prevention, Xicheng District, Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>ZhenGrong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ba</LastName><ForeName>Pian</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>ShuangLi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Ning</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>LiXin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>De</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>WenBo</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>ChunXiang</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>WenZhou</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>XiaoFeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>HuiMing</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Vaccine Immunol</MedlineTA><NlmUniqueID>101252125</NlmUniqueID><ISSNLinking>1556-679X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Vaccine Immunol. 2013 Oct;20(10):1657. doi: 10.1128/CVI.00412-13</RefSource><PMID Version="1">24072885</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Vaccine Immunol. 2013 Oct;20(10):1658. doi: 10.1128/CVI.00432-13</RefSource><PMID Version="1">24072886</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23677325</ArticleId><ArticleId IdType="pmc">PMC3697440</ArticleId><ArticleId IdType="doi">10.1128/CVI.00092-13</ArticleId><ArticleId IdType="pii">CVI.00092-13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC 2011. Progress toward interruption of wild poliovirus transmission&#x2014;worldwide, January 2010-March 2011. MMWR Morb. Mortal. Wkly. Rep. 60:582&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pubmed">21566559</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 1999. Progress toward the global interruption of wild poliovirus type 2 transmission, 1999. MMWR Morb. Mortal. Wkly. Rep. 48:736&#x2013;738, 747</Citation><ArticleIdList><ArticleId IdType="pubmed">10503575</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2006. Resurgence of wild poliovirus type 1 transmission and consequences of importation&#x2014;21 countries, 2002&#x2013;2005. MMWR Morb. Mortal. Wkly. Rep. 55:145&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pubmed">16484977</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2008. Progress toward interruption of wild poliovirus transmission&#x2014;worldwide, January 2007-April 2008. MMWR Morb. Mortal. Wkly. Rep. 57:489&#x2013;494</Citation><ArticleIdList><ArticleId IdType="pubmed">18463607</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2009. Wild poliovirus type 1 and type 3 importations&#x2014;15 countries, Africa, 2008&#x2013;2009. MMWR Morb. Mortal. Wkly. Rep. 58:357&#x2013;362</Citation><ArticleIdList><ArticleId IdType="pubmed">19373195</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2010. Progress toward interruption of wild poliovirus transmission&#x2014;worldwide, 2009. MMWR Morb. Mortal. Wkly. Rep. 59:545&#x2013;550</Citation><ArticleIdList><ArticleId IdType="pubmed">20467412</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2010. Outbreaks following wild poliovirus importations&#x2014;Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb. Mortal. Wkly. Rep. 59:1393&#x2013;1399</Citation><ArticleIdList><ArticleId IdType="pubmed">21048560</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC
2010. 
Outbreak of poliomyelitis in Tajikistan in 2010: risk for importation and impact on polio surveillance in Europe?
Euro Surveill.
15:pii=19558
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19558</Citation><ArticleIdList><ArticleId IdType="pubmed">20460088</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 1999. Progress toward poliomyelitis eradication&#x2014;Myanmar, 1996&#x2013;1999. MMWR Morb. Mortal. Wkly. Rep. 48:967&#x2013;971</Citation><ArticleIdList><ArticleId IdType="pubmed">10553811</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2000. Wild poliovirus imported into Qinghai province, China. Wkly. Epidemiol. Rec. 75:55&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pubmed">11265275</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2000. Importation of wild poliovirus into Qinghai Province&#x2014;China, 1999. MMWR Morb. Mortal. Wkly. Rep. 49:113&#x2013;114</Citation><ArticleIdList><ArticleId IdType="pubmed">11243437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba Y, Murakami H, Kobayashi M, Shimizu H, Yoshida H, Yoneyama T, Miyamura T, Jingjin Y, Libi Z. 2000. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999. Jpn. J. Infect. Dis. 53:135&#x2013;136</Citation><ArticleIdList><ArticleId IdType="pubmed">10957716</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 1997. Manual for the virological investigation of polio. WHO EPI/GEN/97.01.EPI. World Health Organization, Geneva, Switzerland</Citation></Reference><Reference><Citation>CDC 2012. Progress toward interruption of wild poliovirus transmission&#x2014;worldwide, January 2011-March 2012. MMWR Morb. Mortal. Wkly. Rep. 61:353&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">22592275</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2006. Outbreak of type-1 wild poliovirus in adults, Namibia, 2006. Wkly. Epidemiol. Rec. 81:425&#x2013;430</Citation><ArticleIdList><ArticleId IdType="pubmed">17096497</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2006. Outbreak of polio in adults&#x2014;Namibia, 2006. MMWR Morb. Mortal. Wkly. Rep. 55:1198&#x2013;1201</Citation><ArticleIdList><ArticleId IdType="pubmed">17093385</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Menach A, Llosa AE, Mouniaman-Nara I, Kouassi F, Ngala J, Boxall N, Porten K, Grais RF. 2011. Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011. Emerg. Infect. Dis. 17:1506&#x2013;1509</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381570</ArticleId><ArticleId IdType="pubmed">21801636</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC 2000. Outbreak of poliomyelitis&#x2014;Cape Verde, 2000. MMWR Morb. Mortal. Wkly. Rep. 49:1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">11186613</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevots DR, Ciofi degli Atti ML, Sallabanda A, Diamante E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort H, Sutter RW, Tozzi AE, Panei P, Schinaia N, Genovese D, Oblapenko G, Greco D, Wassilak SG. 1998. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin. Infect. Dis. 26:419&#x2013;425</Citation><ArticleIdList><ArticleId IdType="pubmed">9502465</ArticleId></ArticleIdList></Reference><Reference><Citation>. 2010. Poliomyelitis in Tajikistan: first importation since Europe certified polio-free. Wkly. Epidemiol. Rec. 85:157&#x2013;158</Citation><ArticleIdList><ArticleId IdType="pubmed">20449940</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchs A, Cilli A, Russo DH, Costa FF, Carmona Rde C, Timenetsky Mdo C. 2010. Monitoring of poliovirus neutralizing antibodies in Sao Paulo State, Brazil. Trans. R. Soc. Trop. Med. Hyg. 104:625&#x2013;627</Citation><ArticleIdList><ArticleId IdType="pubmed">20708125</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Claus H, Schreier E. 2002. Immunity status against poliomyelitis in Germany: determination of cut-off values in international units. BMC Infect. Dis. 2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC101379</ArticleId><ArticleId IdType="pubmed">11943068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass JW, Halstead SB, Fischer GW, Podgore JK, Wiebe RA. 1978. Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. JAMA 239:2252&#x2013;2255</Citation><ArticleIdList><ArticleId IdType="pubmed">206735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroeni I, Patti AM, Fabrizi A, Santi AL, Manduca AM, Vescia N, Squarcione S, Fara GM. 1997. Immunity status against poliomyelitis in persons 13&#x2013;14 years old living in Rome. Vaccine 15:747&#x2013;750</Citation><ArticleIdList><ArticleId IdType="pubmed">9178477</ArticleId></ArticleIdList></Reference><Reference><Citation>Reali D, Carducci A, Ruschi MA. 1990. Serum antibodies to polioviruses in a Tuscan population, Italy. Eur. J. Epidemiol. 6:309&#x2013;312</Citation><ArticleIdList><ArticleId IdType="pubmed">2174794</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivello R, Farisano G, Bonello C, Moschen ME, Baldo V, Majori S, Moretti G, Marin V, Piron L, Renzulli G. 1994. Immunity status to poliovirus in Veneto region (north-east Italy). A seroepidemiological survey. Ann. Clin. Lab. Sci. 24:542&#x2013;547</Citation><ArticleIdList><ArticleId IdType="pubmed">7847782</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivello R, Renzulli G, Farisano G, Bonello C, Moschen M, Gasparini V, Benussi G. 1988. Persistence of poliovirus-neutralizing antibodies 2&#x2013;16 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice. Epidemiol. Infect. 101:605&#x2013;609</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2249418</ArticleId><ArticleId IdType="pubmed">2850939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamy ME, Cornu C, Desmyter J. 1979. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium. Dev. Biol. Stand. 43:207&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">230111</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. 2005. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect. 11:68&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. 2001. Immunity to poliomyelitis in The Netherlands. Am. J. Epidemiol. 153:207&#x2013;214</Citation><ArticleIdList><ArticleId IdType="pubmed">11157405</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoub BD, Blackburn NK, McAnerney JM. 2001. Seroprevalence to polio in personnel at a virology institute. J. Infect. 43:128&#x2013;131</Citation><ArticleIdList><ArticleId IdType="pubmed">11676519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nates SV, Martinez LC, Barril PA, Ferreyra LJ, Giordano MO, Masachessi G, Isa MB. 2007. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously. Viral Immunol. 20:3&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">17425416</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13:926&#x2013;939</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Claus H, Thierfelder W, Bellach BM, Schreier E. 2000. German health survey 1997/98: immune status against poliomyelitis. Dtsch. Med. Wochenschr. 125:584&#x2013;588 (In German.)</Citation><ArticleIdList><ArticleId IdType="pubmed">11320716</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirez MC, Olivera I, Diabarboure H, Montano A, Baranano R, Badia F, Bonnet MC. 2009. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: implications for future polio vaccination strategies. Vaccine 27:2689&#x2013;2694</Citation><ArticleIdList><ArticleId IdType="pubmed">19428880</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya SC, Agarwal N. 2007. Poliomyelitis: concerns for polio-free countries. Vaccine 25:3245&#x2013;3246</Citation><ArticleIdList><ArticleId IdType="pubmed">17224220</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. 2005. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J. Infect. Dis. 191:990&#x2013;999</Citation><ArticleIdList><ArticleId IdType="pubmed">15717277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. 2007. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro. Surveill. 12:E7&#x2013;E8</Citation><ArticleIdList><ArticleId IdType="pubmed">17991403</ArticleId></ArticleIdList></Reference><Reference><Citation>Falleiros-Carvalho LH. 2009. Polio eradication remains a challenge. Vaccine 27:2731&#x2013;2732</Citation><ArticleIdList><ArticleId IdType="pubmed">19428885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>